Scientists Test New TB Drugs in Korea - Here Is What They Found

Tuberculosis is a serious lung infection that kills millions yearly. Some strains resist the usual medicines. One strain, called isoniazid mono-resistant TB, does not respond to standard treatment. Health experts recommended a 6-month drug mix that includes fluoroquinolone. But does it actually work outside controlled trials?

Korean researchers decided to find out. They tracked 99 patients across multiple hospitals from 2016 to 2024. Every adult had the resistant TB type. About half took the new fluoroquinolone combo. The rest received different medicines. Neither doctors nor patients knew which group they were in. This made the results more honest.

The main goal was simple. Did people recover and stay healthy for at least a year after finishing pills? The fluoroquinolone group hit 71 percent success. The other group reached 73 percent. The tiny gap meant nothing statistically. Both approaches worked equally well. No patient in either group saw their infection return within 12 months.

Side effects raised some eyebrows though. Nearly 29 percent of the fluoroquinolone group faced serious health issues. Liver and bile duct problems topped the list. The comparison group saw issues in about 21 percent of cases. The difference was not large enough to call one option safer than the other.

What does this mean for doctors worldwide? The 6-month fluoroquinolone plan holds up in real hospitals with real patients. It matches older treatments in results. It carries similar risks. Countries struggling with this TB strain now have solid proof that this shorter regimen deserves consideration. Patients might spend less time on toxic drugs while getting the same benefit.